Your results for

Filter by

Filter by
Results

Filter by

Content type
Key content topics
Key audience
Top cancer treatments

Bone Marrow Sparing by Intensity Modulated Proton Beam Therapy in Postoperative Irradiation of Gynecologic Malignancies.

30/10/2024
/ Publications

This matched-pair cohort study from the Heidelberg group evaluated IMPT for 25 patients with uterine cervical (n = 8) or endometrial cancer (n = 17), comparing...

Treatment Tolerability and Toxicity of Postoperative Proton Beam Therapy for Gynecologic Malignancies: Results of the Prospective Phase 2 APROVE Trial.

05/09/2023
/ Publications

This study by the Heidelberg group reported clinical outcomes of 25 patients with uterine cervical or endometrial cancer treated with postoperative PBT. Proton...

Health-related quality of life and patient-reported symptoms after postoperative proton beam radiotherapy of cervical and endometrial cancer: 2-year results of the prospective phase II APROVE-trial.

01/03/2024
/ Publications

The same study as above also reported results of QoL and patient-reported outcomes. QoL status was  markedly impaired at baseline but significantly (p = 0.036)...

Outcomes of Proton Beam Therapy Compared With Intensity-Modulated Radiation Therapy for Uterine Cancer.

01/03/2024
/ Publications

This study reported results of patients with uterine cancer treated with PT (n=22) and IMRT (n=45). When comparing gynecologic-specific subset of PRO-CTCAE, PT...

Outcomes of Patients Treated in the UK Proton Overseas Programme: Non-central Nervous System Group.

01/03/2024
/ Publications

This report presented the results of patients with non-CNS malignancies treated in the UK proton overseas program. Four hundred and ninety-five patients were...

Acute and long-term toxicity of whole pelvis proton radiation therapy for definitive or adjuvant management of gynecologic cancers.

16/05/2023
/ Publications
/
Toxicity

This study reported outcomes of 23 patients with gynecologic malignancies treated with PBSPRT. 12 (52.2%) patients had uterine cancer, 10 (43.5%) cervical, and...